Source: International Congress 2014 – Therapy of thoracic tumours: clinical trials and case series
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
N. Belloumi, N. Ben Salah, S. Toujani, M. Mjid, A. Akad, C. Moussa, A. Hedhli, Y. Ouahchi, B. Louzir, J. Daghfous, N. Mhiri, J. Cherif, M. Beji (Tunis, Tunisia). Symptom-to-treatment intervals in lung cancer. Eur Respir J 2014; 44: Suppl. 58, 2728

Member's Comments

No comment yet.

Related content which might interest you: Methilation status in EBUS-NA samples of lung cancer Source: International Congress 2014 – Improving diagnosis of thoracic tumours Year: 2014 Lung cancer in women: Is it different? Source: International Congress 2014 – Epidemiology, pathogenesis and quality management of thoracic tumours Year: 2014 Relationship between risk factors for lung cancer and tumor size Source: International Congress 2014 – Therapy of thoracic tumours: clinical trials and case series Year: 2014 Second primary lung cancer in squamous NSCLC patients: The Nancy Biobank's database Source: International Congress 2014 – Epidemiology, pathogenesis and quality management of thoracic tumours Year: 2014 Evaluation of lung cancer patients with distant organ metastasis Source: International Congress 2014 – Therapy of thoracic tumours: clinical trials and case series Year: 2014 The value of miR221 and miR222 as a biomarker in non small cell lung cancer Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours Year: 2014 Brain metastatic recurrence following radically treated lung cancer; a retrospective analysis Source: International Congress 2014 – Therapy of thoracic tumours: clinical trials and case series Year: 2014 Functional impairment of NK cells in non-small-cell lung cancer Source: International Congress 2014 – Biology and pathology of thoracic tumours Year: 2014 Metabolomic analysis of serum samples from patients with lung cancer Source: International Congress 2014 – Biology and pathology of thoracic tumours Year: 2014 Comorbitities, responses and survival in pts with NSCLC Source: International Congress 2014 – Epidemiology, pathogenesis and quality management of thoracic tumours Year: 2014 Safety and efficacy of erlotinib in patients with squamous cell lung cancer Source: International Congress 2014 – Therapy of thoracic tumours: clinical trials and case series Year: 2014 Association between leptin and risk of lung cancer Source: International Congress 2016 – Prognostic variables in lung cancer II Year: 2016 Improving NLST criteria for lung cancer screening Source: International Congress 2014 – Improving diagnosis of thoracic tumours Year: 2014 Bronchiolo-alveolar carcinoma- sometimes a difficult diagnosis Source: International Congress 2014 – Diagnosis, imaging and surgery for thoracic tumours Year: 2014 Predictors of lung cancer patients delay time in Serbia - a cross-sectional study Source: International Congress 2014 – Epidemiology, pathogenesis and quality management of thoracic tumours Year: 2014 Assessment of nutritional status in patients with primary lung cancer Source: International Congress 2014 – Therapy of thoracic tumours: clinical trials and case series Year: 2014 Lung cancer, has it changed in the last ten years? Source: International Congress 2015 – Quality management in lung cancer Year: 2015 Serum IL-33 as a diagnostic and prognostic marker in non- small cell lung cancer Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours Year: 2014 Lung cancer in England: Trends in survival over the duration of the national lung cancer audit Source: Annual Congress 2013 –Epidemiology of respiratory disease Year: 2013 EBUS-TBNA for nodal restaging and relapse in lung cancer Source: International Congress 2014 – Diagnosis, imaging and surgery for thoracic tumours Year: 2014